Vivet Therapeutics will be making a presentation on its lead product, VTX-801, at the upcoming 2019 International Liver Congress, April 10-14, Vienna. Dr. Gloria González-Aseguinolaza, Vivet Therapeutics CSO & Head of the Gene Therapy Dept. at FIMA will present “Preclinical validation of copper 64 as a translational tool for evaluating the pharmacodynamics of VTX-801 gene therapy in Wilson disease” (FRI-430; April 12, 2019). VTX-801 is an adeno-associated virus (AAV) containing a gene coding for a functional mini-ATP7B copper transporter, that is intended to restore copper homeostasis through liver cell targeting in Wilson disease.

Dr. Nicholas D Weber, Research Scientist at Vivet Therapeutics, will also be presenting a new animal proof of concept study for one of Vivet’s portfolio indications: “VTX-803 AAV-mediated correction of progressive familiar intrahepatic cholestasis type 3 in a clinically relevant mouse model” (FRI-444 April 12, 2019).